← Leaderboards
Raja G Khalifah
Praetego, Inc.
$5,752,037
Attributed
$5,752,037
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,752,037 · 4
By mechanism
R42$2,598,154 · 1
R44$2,555,118 · 1
R43$299,825 · 1
R41$298,940 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposGlucoseAdvanced Glycosylation End ProductsReactive Oxygen SpeciesProteinsAdductFree RadicalsPharmaceutical PreparationsPreventPropertySafetyLinkDiabeticDrug CandidateTissuesGrantMetalsDiabetes MellitusOxidation-ReductionExhibitsIn VivoComplications Of Diabetes MellitusLeadPeripheral Nervous System Diseases
Grant awards (9)
Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD)$1,246,076
R44 · FY2023 · AG · contact PI
Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy$298,940
R41 · FY2023 · EY · contact PI
Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD)$50,000
R44 · FY2023 · AG · contact PI
Amadorins for Ameliorating Alzheimer's Disease and Related Dementias (ADRD)$1,259,042
R44 · FY2022 · AG · contact PI
Development of novel Amadorins for Diabetic Peripheral Neuropathy$369,966
R42 · FY2022 · DK · contact PI
Development of novel Amadorins for Diabetic Peripheral Neuropathy$895,610
R42 · FY2021 · DK · contact PI
Development of novel Amadorins for Diabetic Peripheral Neuropathy$458,155
R42 · FY2021 · DK · contact PI
Development of novel Amadorins for Diabetic Peripheral Neuropathy$874,423
R42 · FY2020 · DK · contact PI
Development of novel Amadorins for Diabetic Peripheral Neuropathy$299,825
R43 · FY2018 · DK · contact PI